Answers are grounded in this paper and cite their sources.
In a large multicenter cohort of 212 gliptin-associated bullous pemphigoid (GABP) patients, we show that linagliptin-associated BP often presents with a distinctive double-negative (DN) serological phenotype (BP180-NC16A/BP230 negative) and is linked to milder disease severity, supporting a less aggressive therapeutic approach in these patients. From a diagnostic standpoint, our data support the use of an assay based on the ectodomain of BP180 in patients who test negative on commercial BP180-NC16A/BP230 ELISAs.
No takes yet. Share an insight, caveat, or question.
Pira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: